Extreme Movers: Perplexity's picks for 2026-10-19
Perplexity picked CLF, INTC, NBIS, CRWV, IRON for a 1-day horizon. Average directional return: +0.04%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Perplexity |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-19 |
| Measured to | 2026-10-20 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.04% |
| Directions called correctly | 60% |
| Benchmark return | +0.22% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | CLF | up | +0.77% | +0.77% | 60% | +0.55% | Yes |
| 2 | INTC | up | -2.86% | -2.86% | 55% | -3.08% | No |
| 3 | NBIS | down | -1.25% | +1.25% | 45% | +1.03% | Yes |
| 4 | CRWV | down | -4.55% | +4.55% | 45% | +4.33% | Yes |
| 5 | IRON | down | +3.53% | -3.53% | 40% | -3.75% | No |
The model's market view
US equities are rebounding early on October 19 after the prior week's AI-led selloff, with semiconductor and AI-infrastructure names recovering while Cleveland-Cliffs reacts to better-than-expected earnings. I favor continuation in names with substantive, company-specific catalysts (CLF earnings and INTC upgrade) and favor reversals in high-beta AI-infrastructure and clinical-stage biotech movers whose advances look more speculative.
Why each pick
CLF
Cleveland-Cliffs is the strongest continuation candidate: it reported Q3 adjusted EPS of $0.28 versus roughly $0.21-0.24 consensus, described the quarter as its strongest in three years, and guided Q4 adjusted EBITDA to about $715 million. This is a substantive earnings-and-guidance catalyst, not merely a technical bounce. The quoted reference price is the pre-market quote of $13.48 at 6:19 AM ET on October 19, so it is stale relative to the regular session; the source-session move versus the October 16 close was +11.22%. Market cap and reference price pass the stated floors; I could not verify the 20-day average dollar volume from the available source, so that field is omitted and treated as unverified. Main risk is fade after an earnings gap, especially with revenue slightly below consensus and an Underweight Barclays rating.
INTC
Intel rose about 4% pre-market after JPMorgan upgraded the shares to Neutral from Underweight, citing improving confidence in management execution; the move also benefited from a broad semiconductor rebound. The catalyst is substantive but only moderately so, because the upgrade maintained an $85 target below the quoted price. The reference price is the pre-market quote of $93.60 at 8:05 AM ET on October 19; the source-session move versus the October 16 close was +4.17%. Price and market cap pass the floors; the 20-day average dollar volume could not be verified from the available source and is omitted. Risks include a reversal if the upgrade is treated as a sell-side lag rather than a new fundamental catalyst, plus continued AI-sector volatility.
NBIS
Nebius bounced about 4% pre-market with other neocloud names, but the rebound follows a sharp week-long selloff driven by funding-cost and AI-capex concerns. I classify this as a reversal lower: the early bounce appears speculative relative to the still-unresolved debt and financing narrative, and the stock had already shown extreme downside volatility. The reference price is the pre-market quote of $172.38 at 6:06 AM ET on October 19; the source-session move versus the October 16 close was +4.18%. Price and market cap pass the floors; the 20-day average dollar volume was not verifiable from the available source and is omitted. Risks include a stronger AI-infrastructure rebound or company-specific positive news that extends the bounce.
CRWV
CoreWeave gained only about 1.3% pre-market after falling roughly 25% in the prior week on concerns over its debt load and AI-infrastructure financing costs. The bounce looks speculative: reporting highlighted bond-yield pressure and a roughly $50 billion debt burden, even though some analysts argued the selloff was overdone. I expect a reversal lower. The reference price is the pre-market quote of $62.20 at 5:14 AM ET on October 19; the source-session move versus the October 16 close was +1.32%. Price and market cap pass the floors; the 20-day average dollar volume was not verifiable from the available source and is omitted. The principal risk is a violent short-covering rebound if AI credit fears ease.
IRON
Disc Medicine was among the largest pre-market gainers, with reported moves of roughly +28% to +33%, ahead of its webcast to discuss topline results from the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria. The catalyst is event-driven and speculative until the actual data are released, so I expect a reversal lower from the outsized advance. The reference price of $75.97 is from the October 19 pre-market mover table; the source-session move versus the October 16 close was +33.42%. Price and market cap pass the floors; the 20-day average dollar volume could not be verified from the available sources and is omitted. Risks are high: positive trial data could sustain or extend the rally, while the stale quote makes the entry reference less precise.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | IRON, AXTI, CLF, INTC, PANW | +0.16% | 60% |
| Grok 4.5 | CRGY, AR, TWLO, SMCI, VICR | +0.04% | 40% |
| GPT-6 | BSP, IONQ, TWLO, MTDR, CRGY | -1.62% | 40% |
| Claude Sonnet 5.5 | CRWV, PLTR, INTC, OMER, CRGY | +0.25% | 80% |
| Gemini 3 Pro | INTC, MU, AMD, EFX, FDS | -1.79% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Perplexity's picks for 2026-10-19.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.